每经AI快讯，爱美客（300896.SZ）1月30日在投资者互动平台表示，公司经销的肉毒毒素产品最近取得 药品注册证书，公司正在制定相关的销售策略，关于产品销售情况敬请关注公司公告。 （文章来源：每日经济新闻） ...

智通财经APP获悉，据港交所1月30日披露，征祥医药(南京)集团股份有限公司(以下简称"征祥医药")向 港交所主板递交上市申请，中金公司为其独家保荐人。据招股书，征祥医药是一家处于商业化阶段的生 物制药公司，致力于发现、开发及商业化创新疗法，以解决病毒性传染病、肿瘤学及炎症性疾病领域未 被满足的医疗需求。 征祥医药的核心产品玛硒洛沙韦片为靶向流感病毒聚合酶酸性蛋白("PA")核酸内切酶的抑制剂，已于 2025年7月获得国家药品监督管理局("国家药监局")用于治疗成人流感的新药申请("NDA")批准，且该公 司正将其适应症扩展至青少年患者及暴露后预防领域。利用商业化药物资产及综合小分子药物研发平 台，征祥医药已开发出六个药物资产管线，包括该公司的商业化玛硒洛沙韦片、一款针对儿童流感患者 的临床后期玛硒洛沙韦干混悬剂型、一款用于治疗实体瘤的ZX-8177(一期临床阶段)，以及针对人类乳 头瘤病毒("HPV")感染的处于IND申报阶段的ZX-12042B药物。征祥医药还有两种针对单纯疱疹病毒 ("HSV")感染及自身免疫性疾病的临床前候选药物。 | 纂 的[编纂]數目 : [编纂]股H股(視乎[编纂]行使與否而定) ...

Core Insights - The article discusses recent advancements in the medical field, particularly focusing on new cholesterol-lowering drugs and metabolic drugs like tirzepatide, which are being researched for cardiovascular outcomes [1] - There is a notable trend in the industry towards the use of AI in drug development, gene editing, and synthetic biology, which is expected to enhance efficiency from research and development to production [1] - Chinese companies, including Huaxi Biological, are actively investing in synthetic biology and biomanufacturing to improve the scalability and accessibility of certain bioactive components [1] Group 1 - Recent approvals of new cholesterol-lowering drugs and ongoing research into metabolic drugs are significant developments in the healthcare sector [1] - AI-assisted technologies are accelerating the efficiency of drug development and production, potentially lowering costs and increasing accessibility [1] - The need for more clinical evidence and long-term follow-up to validate the safety and effectiveness of these new technologies remains a critical consideration [1] Group 2 - Companies like Huaxi Biological are focusing on synthetic biology and biomanufacturing to enhance the production of bioactive components [1] - There is an emphasis on early risk identification and management of lifestyle and chronic disease indicators as practical health strategies for the general public [1]

Group 1 - The core point of the article is that Tonghua Dongbao received a warning from the Jilin Securities Regulatory Bureau due to issues regarding the independence of the company and its major shareholder, Dongbao Industrial Group [1][3] - The company has been found to have mutual use of certain properties with its controlling shareholder without signed lease agreements or rent payments, indicating a lack of independence [3] - The chairman, Li Jiahong, is primarily responsible for these violations, and the regulatory body has decided to impose corrective measures and issue a warning letter [3] Group 2 - On January 29, Dongbao Industrial Group pledged 21 million shares of Tonghua Dongbao to China Construction Bank for debt repayment, representing 1.07% of the company's total share capital [3] - As of the announcement date, Dongbao Industrial Group holds a total of 620 million shares, with 586 million shares pledged, accounting for 29.94% of the total share capital and 94.66% of the shareholder's holdings [3] - Just days before the warning letter, Tonghua Dongbao announced a positive earnings forecast for 2025, expecting a net profit of approximately 1.242 billion yuan, marking a significant turnaround from the previous year [3][4] Group 3 - The company's turnaround in performance is attributed to two main factors: the successful bidding for insulin products in the domestic market and significant growth in other products like liraglutide injection and empagliflozin tablets [4] - Notably, a substantial portion of the net profit increase is due to a one-time gain from the sale of shares in Xiamen Te Bao Biological Engineering Co., which contributed over 800 million yuan, accounting for about 64% of the total net profit [4][5] - This indicates that the impressive performance in 2025 is largely driven by a non-recurring asset sale rather than core business operations [5]

Core Insights - The company, Junshi Biosciences (688180.SH), expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year increase of about 28.32% [1] - The projected R&D expenses for 2025 are around 1.353 billion yuan, reflecting a growth of 6.10% compared to the previous year [1] - The net profit attributable to the parent company is expected to be a loss of approximately 873 million yuan, which is a reduction in loss of 31.85% year-on-year [1] Revenue and Profitability - The company anticipates a net profit of approximately -795 million yuan after excluding share-based payment impacts, which indicates a year-on-year loss reduction of 37.62% [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be around -985 million yuan, showing a decrease in loss of 23.64% compared to the previous year [2] - The sales revenue growth is primarily driven by the commercialization of pharmaceutical products, particularly the core product, Toripalimab injection (brand name: Tuoyi®), which has seen significant sales growth in the domestic market [2] Product and Market Expansion - As of the announcement date, Tuoyi® has been included in the national medical insurance directory for all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody for treating renal cancer, triple-negative breast cancer, and melanoma in the directory [2] - The company is actively expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including mainland China, Hong Kong, the United States, the European Union, India, the United Kingdom, and several others [2]

Core Insights - The company, Junshi Biosciences (688180.SH), expects to achieve an annual revenue of approximately 2.5 billion yuan in 2025, representing a year-on-year increase of about 28.32% [1] - The projected R&D expenses for 2025 are around 1.353 billion yuan, reflecting a growth of 6.10% compared to the previous year [1] - The company anticipates a net loss attributable to shareholders of approximately 873 million yuan for 2025, which is a reduction of 31.85% from the previous year's loss [1] Revenue and Profitability - The expected revenue growth is primarily driven by increased sales of commercialized drugs, particularly the core product, Toripalimab injection (brand name: Tuoyi®) [2] - The net loss, after excluding share-based payment impacts, is projected to be around 799 million yuan, indicating a significant reduction of 37.62% year-on-year [1] Product Performance - Toripalimab injection has seen substantial sales growth in the domestic market, with all 12 approved indications included in the national medical insurance catalog [2] - The product is the only anti-PD-1 monoclonal antibody listed for the treatment of renal cancer, triple-negative breast cancer, and melanoma in the catalog [2] - The company is expanding its global commercialization network, with Toripalimab approved for sale in over 40 countries and regions, including the U.S., EU, and several Asian countries [2]

(一)主营业务的影响。2025年度公司核心产品泰它西普、维迪西妥单抗国内销售收入实现快速增长，成 为业绩核心增长引擎;同时，公司成功达成重磅合作，授予Vor Biopharma Inc泰它西普除大中华区以外全 球范围内的独家开发与商业化权利，技术授权收入大幅增加，部分海外研发投入由授权方承担。此外， 公司通过优化管理、迭代生产工艺等举措，降低了产品单位生产成本，提升了产品毛利率，另外，销售 费用率明显下降。综合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为 盈。 本期业绩变化的主要原因： 智通财经APP讯，荣昌生物(09995)发布公告，经公司财务部门初步测算，预计2025年度营业收入约人民 币32.5亿元，与上年同期相比，将增加收入约人民币15.33亿元，同比增加约89%。公司预计2025年度实 现归属于母公司所有者的净利润约人民币7.16亿元，与上年同期相比，实现扭亏为盈。公司预计2025年 度归属于母公司所有者扣除非经常性损益后的净利润约人民币7850万元，与上年同期相比，实现扭亏为 盈。 (二)非经常性损益的影响。2025年度自上述授权交易取得的认股权证公允价值变动属于非经常 ...

证券日报网讯1月30日，智飞生物（300122）在互动平台回答投资者提问时表示，公司高度重视研发创 新，形成智飞绿竹、智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，实现"预防 &治疗"协同发展。目前人二倍体狂犬病疫苗、四价流脑结合疫苗、15价肺炎结合疫苗及利拉鲁肽注射 液处于上市审评阶段。 ...

Group 1 - The core announcement is that Boya Bio has received approval from the National Medical Products Administration for three specifications of intravenous human immunoglobulin (pH4) [1] - The approval was granted to Green Cross (China) Biological Products Co., Ltd., a wholly-owned subsidiary of Green Cross Hong Kong Holdings Limited, which is itself a wholly-owned subsidiary of Boya Bio [1] - The approval notification includes three specific notification numbers: 2026B00463, 2026B00465, and 2026B00466 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 本公告由榮昌生物製藥（煙台）股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則第13.09(2)(a)條及第13.10B條項下披露責任以及證券及期貨條 例（香港法例第571章）第XIVA部項下的內幕消息條文作出。 本公司於本公告載列2025年度（「本期」）財務數據，數據乃根據《中國企業會計準 則》編製，且僅為初步會計數據，未經會計所審計。本公告所載數據與本公司年 報所披露的最終數據或有區別。投資者在買賣本公司股份時務請審慎行事。 一、本期業績預告情況 （一）業績預告期間 2025年1月1日至2025年12月31日。 1 （二）業績預告情況 (1) 經本公司財務部門初步測算，預計2025 年度營業收入約人民幣 325,000萬元，與 ...